Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00921_DB01168_nanopub.RAJUw3XB3qCHVN-7LXhL3jgcFjphY6Q61bFIZsP8sKQ7w#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00921_DB01168 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00921_DB01168 label "DDI between Buprenorphine and Procarbazine - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. [drugbank_resource:DB00921_DB01168]" assertion.
- drugbank_resource:DB00921_DB01168 identifier "drugbank_resource:DB00921_DB01168" assertion.
- drugbank_resource:DB00921_DB01168 title "DDI between Buprenorphine and Procarbazine - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects." assertion.
- drugbank:DB00921 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00921_DB01168 assertion.
- drugbank:DB01168 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00921_DB01168 assertion.